发布求助
文献互助 智能选刊 最新文献

Medical Letter on Drugs and Therapeutics最新文献

筛选
英文 中文
Aprocitentan (Tryvio) for hypertension. 治疗高血压的 Aprocitentan（Tryvio）。
IF 1.4 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-06-10 DOI: 10.58347/tml.2024.1704b
{"title":"Aprocitentan (Tryvio) for hypertension.","authors":"","doi":"10.58347/tml.2024.1704b","DOIUrl":"https://doi.org/10.58347/tml.2024.1704b","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141437759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tislelizumab (Tevimbra) for esophageal cancer. 治疗食道癌的 Tislelizumab（Tevimbra）。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-05-13 DOI: 10.58347/tml.2024.1702h
{"title":"Tislelizumab (Tevimbra) for esophageal cancer.","authors":"","doi":"10.58347/tml.2024.1702h","DOIUrl":"https://doi.org/10.58347/tml.2024.1702h","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intravenous acetaminophen/ibuprofen (Combogesic IV). 静脉注射对乙酰氨基酚/布洛芬（Combogesic IV）。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-04-29 DOI: 10.58347/tml.2024.1701c
{"title":"Intravenous acetaminophen/ibuprofen (Combogesic IV).","authors":"","doi":"10.58347/tml.2024.1701c","DOIUrl":"https://doi.org/10.58347/tml.2024.1701c","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140855975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison Table: Some Topical Drugs for Rosacea. 对照表：一些治疗红斑痤疮的外用药物
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-04-29 DOI: 10.58347/tml.2024.1701f
{"title":"Comparison Table: Some Topical Drugs for Rosacea.","authors":"","doi":"10.58347/tml.2024.1701f","DOIUrl":"https://doi.org/10.58347/tml.2024.1701f","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140867335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lifileucel (Amtagvi): A cellular therapy for melanoma. Lifileucel（Amtagvi）：一种治疗黑色素瘤的细胞疗法。
IF 1.4 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-04-29 DOI: 10.58347/tml.2024.1701h
{"title":"Lifileucel (Amtagvi): A cellular therapy for melanoma.","authors":"","doi":"10.58347/tml.2024.1701h","DOIUrl":"10.58347/tml.2024.1701h","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140868753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A new indication for semaglutide (Wegovy). semaglutide（Wegovy）的新适应症。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-04-29 DOI: 10.58347/tml.2024.1701b
{"title":"A new indication for semaglutide (Wegovy).","authors":"","doi":"10.58347/tml.2024.1701b","DOIUrl":"https://doi.org/10.58347/tml.2024.1701b","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140873545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
iDose TR - a travoprost implant for glaucoma. iDose TR - 一种用于青光眼的曲伏前列素植入物。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-04-29 DOI: 10.58347/tml.2024.1701d
{"title":"iDose TR - a travoprost implant for glaucoma.","authors":"","doi":"10.58347/tml.2024.1701d","DOIUrl":"https://doi.org/10.58347/tml.2024.1701d","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140853641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Belzutifan (Welireg) for advanced renal cell carcinoma. 贝珠替凡（Welireg）治疗晚期肾细胞癌。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-04-29 DOI: 10.58347/tml.2024.1701g
{"title":"Belzutifan (Welireg) for advanced renal cell carcinoma.","authors":"","doi":"10.58347/tml.2024.1701g","DOIUrl":"https://doi.org/10.58347/tml.2024.1701g","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140867661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antibiotic prophylaxis for dental procedures. 牙科手术的抗生素预防。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-04-29 DOI: 10.58347/tml.2024.1701e
{"title":"Antibiotic prophylaxis for dental procedures.","authors":"","doi":"10.58347/tml.2024.1701e","DOIUrl":"10.58347/tml.2024.1701e","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resmetirom (Rezdiffra) for metabolic dysfunction-associated steatohepatitis. Resmetirom（Rezdiffra）治疗代谢功能障碍相关性脂肪性肝炎。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-04-29 DOI: 10.58347/tml.2024.1701a
{"title":"Resmetirom (Rezdiffra) for metabolic dysfunction-associated steatohepatitis.","authors":"","doi":"10.58347/tml.2024.1701a","DOIUrl":"10.58347/tml.2024.1701a","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140868282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信